{"ok":true,"entry":{"slug":"medroxyprogesterone","kind":"medication","name":"medroxyprogesterone","aliases":["Provera","Depo-Provera"],"brands_sg":["Provera","Depo-Provera"],"class":"progestogen","tags":["hormonal"],"use_for":"prescribed for abnormal uterine bleeding, and for hrt","use_after":"healthhub: after food, at the same time each day","use_duration":null,"take_with":"food · healthhub: taken after food to ease stomach upset","pros":["healthhub: a progestogen for heavy or absent periods","fda: oral label states 5 or 10 mg daily for 5–10 days","depo-provera: one 150 mg injection every 3 months"],"cons":["boxed warning: clot, stroke, breast-cancer risk in hrt","depo boxed warning: significant bone mineral loss","healthhub: nausea, breast tenderness, mood swings"],"dose_note":"the us label for medroxyprogesterone acetate tablets states 'MPA tablets may be given in dosages of 5 or 10 mg daily for 5 to 10 days' for secondary amenorrhoea, and '10 mg of MPA daily for 10 days' for secretory transformation — 10 mg a day is the highest daily amount the oral label states, and the sg register carries provera 5 mg and 10 mg tablets. the separate depo-provera contraceptive injection label states 'The recommended dose is 150 mg of Depo-Provera CI every 3 months (13 weeks)'. in singapore the prescriber sets the dose.","dosage":null,"ul_status":null,"sg_class":"prescription-only","cautions":["undiagnosed abnormal genital bleeding — fda: contraindicated","current or past clots, stroke or heart attack — fda: contraindicated","known or suspected breast cancer — fda: contraindicated","liver impairment, or known or suspected pregnancy — fda: contraindicated"],"clashes":[{"src":["fda_mpa_di"],"note":"fda: may lower plasma levels of contraceptive hormones and reduce contraceptive effectiveness","with":"enzyme inducers (carbamazepine, phenytoin, rifampin, topiramate)"},{"src":["fda_mpa_di"],"note":"fda: listed among products that may decrease the effectiveness of hormonal contraceptives","with":"st john's wort"},{"src":["fda_mpa_di"],"note":"fda: significant increases or decreases in progestin plasma levels have been reported","with":"hiv protease inhibitors and nnrtis"},{"src":["fda_mpa_boxed"],"note":"fda boxed warning: oestrogen plus progestin raised dvt, pe, stroke, mi, breast cancer and probable dementia in the whi","with":"oestrogen (as combined hrt)"}],"sources":[{"id":"hsa_register","url":"https://data.gov.sg/datasets/d_767279312753558cbf19d48344577084/view","label":"HSA — Listing of Registered Therapeutic Products (data.gov.sg open dataset, 5,511 rows; cached at /tmp/hsa_all.json and filtered locally, not re-fetched)","quote":"All 3 registered medroxyprogesterone products read Forensicclassification 'Prescription Only' — SIN10513P PROVERA TABLET 5 mg · SIN03841P PROVERA TABLET 10 mg (G03DA02) · SIN04540P DEPO-PROVERA STERILE AQUEOUS SUSPENSION 50 mg/ml (G03AC06)","accessed":"2026-08-27"},{"id":"hh_mpa_uses","url":"https://www.healthhub.sg/medication-devices-and-treatment/medications/medroxyprogesterone","label":"HealthHub (Pharmaceutical Society of Singapore) — Medroxyprogesterone: what is this medication for","quote":"Medroxyprogesterone is a type of progestogen … Management of various abnormal uterine bleeding including absence of menstrual flow and heavy menstrual bleeding … Management of menopause in combination with estrogen replacement therapy","accessed":"2026-08-27"},{"id":"hh_mpa_admin","url":"https://www.healthhub.sg/medication-devices-and-treatment/medications/medroxyprogesterone","label":"HealthHub — Medroxyprogesterone: how should I take or use this medication","quote":"This medicine should be taken after food … Take medication at the same time every day to avoid huge changes in the hormone levels in your body","accessed":"2026-08-27"},{"id":"hh_mpa_se","url":"https://www.healthhub.sg/medication-devices-and-treatment/medications/medroxyprogesterone","label":"HealthHub — Medroxyprogesterone: common side effects","quote":"Stomach discomfort, nausea and vomiting. Take it after food to reduce these side effects. Breast tenderness. Headache … Dizziness, drowsiness … Weight changes, mood swings … Skin pigmentation.","accessed":"2026-08-27"},{"id":"fda_mpa_ind","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22MEDROXYPROGESTERONE+ACETATE%22+AND+openfda.route:%22ORAL%22&limit=5","label":"US FDA label for medroxyprogesterone acetate tablets (Mylan), Indications and Usage, via openFDA (effective 2026-05-21)","quote":"indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology … prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women","accessed":"2026-08-27"},{"id":"fda_mpa_dose","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22MEDROXYPROGESTERONE+ACETATE%22+AND+openfda.route:%22ORAL%22&limit=5","label":"US FDA label for medroxyprogesterone acetate tablets (Mylan), Dosage and Administration, via openFDA","quote":"MPA tablets may be given in dosages of 5 or 10 mg daily for 5 to 10 days … 10 mg of MPA daily for 10 days … Patients should be started at the lowest dose","accessed":"2026-08-27"},{"id":"fda_mpa_ci","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22MEDROXYPROGESTERONE+ACETATE%22+AND+openfda.route:%22ORAL%22&limit=5","label":"US FDA label for medroxyprogesterone acetate tablets (Mylan), Contraindications, via openFDA","quote":"Undiagnosed abnormal genital bleeding. Known, suspected, or history of breast cancer … Active DVT, PE, or a history of these conditions … Known liver impairment or disease. Known or suspected pregnancy.","accessed":"2026-08-27"},{"id":"fda_mpa_boxed","url":"https://api.fda.gov/drug/label.json?search=openfda.generic_name:%22MEDROXYPROGESTERONE+ACETATE%22+AND+openfda.route:%22ORAL%22&limit=5","label":"US FDA label for medroxyprogesterone acetate tablets (Mylan), Boxed Warning, via openFDA","quote":"reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke and myocardial infarction (MI) … an increased risk of developing probable dementia … an increased risk of invasive breast cancer","accessed":"2026-08-27"},{"id":"fda_depo_dose","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22PROVERA%22&limit=1","label":"US FDA label for DEPO-PROVERA CI (medroxyprogesterone acetate injectable suspension), section 2, via openFDA (effective 2025-12-18)","quote":"The recommended dose is 150 mg of Depo-Provera CI every 3 months (13 weeks) administered by deep, intramuscular (IM) injection in the gluteal or deltoid muscle.","accessed":"2026-08-27"},{"id":"fda_depo_boxed","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22PROVERA%22&limit=1","label":"US FDA label for DEPO-PROVERA CI, Boxed Warning, via openFDA","quote":"Women who use Depo-Provera Contraceptive Injection (Depo-Provera CI) may lose significant bone mineral density. Bone loss is greater with increasing duration of use and may not be completely reversible.","accessed":"2026-08-27"},{"id":"fda_mpa_di","url":"https://api.fda.gov/drug/label.json?search=openfda.brand_name:%22PROVERA%22&limit=1","label":"US FDA label for DEPO-PROVERA CI, section 7 Drug Interactions, via openFDA","quote":"Some drugs or herbal products that may decrease the effectiveness of hormonal contraceptives include: barbiturates, bosentan, carbamazepine, felbamate, griseofulvin, oxcarbazepine, phenytoin, rifampin, St. John's wort, topiramate","accessed":"2026-08-27"}],"brand_certs":null,"updated_at":"2026-08-29T16:16:24.715168+08:00"},"disclaimer":"kozen-x is not a medical device and does not give medical advice. it lists what published sources have written down. absence of a record is not the same as safe."}